Loading...
The anti-CD52 monoclonal antibody alemtuzumab is approved for the management of chronic lymphocytic leukemia and is being investigated for the prevention of transplant rejection, control of autoimmune disease, and treatment of multiple sclerosis (MS). However, in the prior CAMM223 phase II trial of alemtuzumab for MS, a number of patients with relapsing-remitting disease who received alemtuzumab (12 mg or 24 mg/day for 3 to 5 days during 2 or 3 annual cycles) developed autoimmune disorders, including severe late-onset immune thrombocytopenia (ITP; N Engl J Med 2008; 359:1786).
Now, investigators have further characterized ITP in MS patients from the CAMM223 study. They found that during a median follow-up of 4.5 years, ITP occurred in 2 (1.9…